ProtecT Study Publications Summary

84 Seasonal variation in prostate specific antigen levels: a large cross-sectional study of men in the UK
BJU International
2011
Down L; Metcalfe C; Martin RM; Neal DE; Hamdy FC; Donovan JL; Lane JA

105 Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose-response meta-analysis
Cancer Causes and Control
2011, 22: 319-340
Gilbert R; Martin RM; Beynon R; Harris R; Savovic J; Zuccolo L; Bekkering GE; Fraser WD; Sterne JAC; Metcalfe C

125 A Peer Review Intervention for Monitoring and Evaluation (PRIME) of sites that improved randomised controlled trial conduct and performance
Journal of Clinical Epidemiology
2011, 64: 628-636
Lane JA; Wade J; Bonnington S; Down L; Holding PN; Lennon T; Jones AJ; Salter L; Neal DE; Hamdy FC; Donovan JL

133 Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study
British Journal of Cancer
2011, 104: 875-881
Dimitropoulou P; Martin RM; Turner EL; Lane JA; Gilbert R; Davis MJ; Donovan JL; Hamdy FC; Neal DE

147 Validation of a modelling approach for estimating the likely effectiveness of cancer screening using cancer data on prevalence screening and incidence
Cancer Epidemiology
2011, 35: 139-144
Pashayan N; Pharoah P; Tabar L; Neal DE; Martin RM; Donovan JL; Hamdy FC; Duffy SW

156 Exploring treatment preferences facilitated recruitment to randomised controlled trials
Journal of Clinical Epidemiology
2011, 64: 1127-1136
Mills N; Donovan JL; Wade J; Hamdy FC; Neal DE; Lane JA
Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study

Nature Genetics
2011, 43: 785-792
Kote Jarai Z

Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study

British Journal of Cancer
2011, 105: 931-937
Catto JW; Robinson MC; Albertsen P; Goepel JR; Abbod MF; Linkens DA; Davis MJ; Rosario DJ; Warren AY; Varma M; Griffiths DF; Grigor KM; Mayer NJ; Oxley J; Deshmukh NS; Lane JA

Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result

British Journal of Cancer
2010, 102: 1335-1340
Macefield RC; Metcalfe C; Lane JA; Donovan JL; Avery KNL; Blazeby JM; Down L; Neal DE; Hamdy FC; Vedhara K

Associations of aspirin, non-steroidal anti-inflammatory drug and paracetamol use with PSA detected prostate cancer: findings from a large, population-based, casecontrol study (the ProtecT study)

International Journal of Cancer
2010, 128: 1442-1448
Murad AS; Down L; Davey Smith G; Hamdy FC; Neal DE; Donovan JL; Martin RM

A polymorphism in the glucokinase gene that raises plasma fasting glucose, rs1799884, is associated with diabetes mellitus and prostate cancer

International Journal of Molecular Epidemiology and Genetics
2010, 1: 175-183
Murad AS; Davey Smith G; Lewis SJ; Cox A; Hamdy FC; Neal DE; Donovan JL; Martin RM

Evaluation of association of HNF1B variants with diverse cancers: collaborative analysis of data from 19 genome-wide association studies

PLoS ONE
2010, 5
Elliott KS; Zeggini E; McCarthy MI; Gudmundsson J; Sulem P; Stacey SN; Thorlacius S; Amundadottir L; Gronberg H; Xu J; Gaborieau V; Eeles RA; Neal DE; Donovan JL; Hamdy FC; Muir KM

ProtecT-related papers in press or published - short report

30/09/2011
132 Circulating folate, vitamin B12, homocysteine, and vitamin B12 transport proteins in relation to prostate cancer risk: a case-control study, systematic review and meta-analysis
Cancer Epidemiology Biomarkers and Prevention
2010, 19: 1632-1642
Collin SM

137 Association of diabetes mellitus with prostate cancer: nested case-control study (ProtecT: Prostate testing for cancer and Treatment)
International Journal of Cancer
2010, 128: 440-446
Turner EL; Lane JA; Donovan JL; Davis MJ; Metcalfe C; Neal DE; Hamdy FC; Martin RM

138 PSA-detected prostate cancer and the potential of dedifferentiation - estimating the proportion capable of progression
International Journal of Cancer
2010
Pashayan N; Pharoah P; Neal DE; Hamdy FC; Donovan JL; Martin RM; Greenberg DC; Duffy SW

142 The Potential Value of Microseminoprotein-beta as a Prostate Cancer Biomarker and Therapeutic Target
Prostate
2010, 70: 333-340
Whitaker HC; Warren AY; Eeles RA; Kote Jarai Z; Neal DE

144 The relation between adiposity throughout the life course and variation in IGFs and IGFBPs: evidence from the ProtecT (Prostate testing for cancer and Treatment) study
Cancer Causes Control
2010, 21: 1829-1842
Rowlands MA; Holly JMP; Gunnell DJ; Gilbert R; Donovan JL; Lane JA; Marsden G; Collin SM; Hamdy FC; Neal DE; Martin RM

145 Associations between an obesity related genetic variant (FTO rs9939609) and prostate cancer risk
PLoS ONE
2010, 10
Lewis SJ; Murad AS; Chen L; Davey Smith G; Donovan JL; Palmer T; Hamdy FC; Neal DE; Lane JA; Davis MJ; Cox A; Martin RM

151 Latest results from the UK trials evaluating prostate cancer screening and treatment: The CAP and ProtecT studies
European Journal of Cancer
2010, 46: 3095-3101
Lane JA; Hamdy FC; Martin RM; Turner EL; Neal DE; Donovan JL
157 Associations of folate, vitamin B12, homocysteine, and folate-pathway polymorphisms with PSA velocity in men with localized prostate cancer
Cancer Epidemiology Biomarkers and Prevention
2010, 19: 2833-2838
Gilbert R; Martin RM; Beynon R; Harris R; Savovic J; Zuccolo L; Bekkering GE; Fraser WD; Sterne JAC; Metcalfe C

159 Metabolic imbalance and prostate cancer progression
International Journal of Molecular Epidemiology and Genetics
2010, 1: 248-271
Burton A; Tilling K; Holly JMP; Hamdy FC; Rowlands MA; Donovan JL; Martin RM

57 Factors distinguishing general practitioners who more readily participated in a large randomized trial were identified
Journal of Clinical Epidemiology
2009, 62: 67-73
Down L; Metcalfe C; Avery KNL; Noble S; Lane JA; Neal DE; Hamdy FC; Donovan JL

59 Development of a complex intervention improved randomisation and informed consent in a randomised controlled trial
Journal of Clinical Epidemiology
2009, 62: 29-36
Donovan JL; Lane JA; Peters TJ; Brindle LA; Salter L; Gillatt D; Powell PH; Bollina P; Neal DE; Hamdy FC

64 It’s not just what you say, it’s also how you say it: Opening the ‘black box’ of informed consent appointments in randomised controlled trials
Social Science & Medicine
2009, 68: 2018-2028
Wade J; Donovan JL; Lane JA; Neal DE; Hamdy FC

69 Life course sun exposure and risk of prostate cancer: population-based nested case-control study (ProtecT)
International Journal of Cancer
2009, 125: 1414-1423
Gilbert R; Metcalfe C; Oliver SE; Whiteman DC; Bain C; Ness A; Donovan JL; Hamdy FC; Neal DE; Lane JA; Martin RM

71 Genetic Variants in the Vitamin D Receptor Are Associated with Advanced Prostate Cancer at Diagnosis: Findings from the Prostate Testing for Cancer and Treatment Study and a Systematic Review
Cancer Epidemiology Biomarkers and Prevention
2009, 18: 2874-2881
Chen L; Davey Smith G; Evans DM; Cox A; Lawlor DA; Donovan JL; Yuan W; Day INM; Martin RM; Lane JA; Rodriguez S; Davis MJ; Zuccolo L; Collin SM; Hamdy FC; Neal DE
85 Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy?
European Journal of Cancer
2009, 45: 2569-2573
Macefield RC; Lane JA; Metcalfe C; Down L; Hamdy FC; Neal DE; Donovan JL

93 Feasibility and cost of obtaining informed consent for essential review of medical records in large-scale public health research
Journal of Health Services Research & Policy
2009, 14: 77-81
Noble S; Donovan JL; Turner EL; Metcalfe C; Lane JA; Rowlands MA; Neal DE; Hamdy FC; Ben Shlomo Y; Martin RM

95 Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review & meta-analysis
International Journal of Cancer
2009, 124: 2416-2429
Rowlands MA; Gunnell DJ; Harris R; Vatten LJ; Holly JMP; Martin RM

100 PTGS2 –899G>C and prostate cancer risk: population-based nested case-control study (ProtecT) and a systematic review with meta-analysis
Prostatic Cancer and Prostatic Diseases
2009, 12: 296-300
Murad AS; Martin RM; Chen L; Donovan JL; Hamdy FC; Neal DE; Davey Smith G; Lewis SJ

102 Association of Folate-Pathway Gene Polymorphisms with the Risk of Prostate Cancer: a Population-Based Nested Case-Control Study, Systematic Review, and Meta-analysis
Cancer Epidemiology, Biomarkers and Prevention
2009, 18: 2528-2539
Collin SM; Martin RM; Lewis SJ

103 Associations of sexual dysfunction symptoms with PSA-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study
European Journal of Cancer
2009, 45: 3254-3261
Collin SM; Metcalfe C; Donovan JL; Lane JA; Neal DE; Hamdy FC; Davis MJ; Martin RM
Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening

British Journal of Cancer
2009, 100: 1198-1204
Pashayan N; Duffy SW; Pharoah P; Greenberg DC; Donovan JL; Martin RM; Hamdy FC; Neal DE

Identification of new genetic risk factors for prostate cancer

Asian Journal of Andrology
2009, 11: 49-55
Guy M

Development of a New Method for Monitoring Prostate-Specific Antigen Changes in Men with Localised Prostate Cancer: A Comparison of Observational Cohorts

European Urology
2009, 57: 446-452
Tilling K; Garmo H; Metcalfe C

Population-based prostate-specific antigen testing in the UK leads to stage migration of prostate cancer

British Journal of Urology International
2009, 104: 1592-1598
Moore AL; Dimitropoulou P; Lane JA; Powell PH; Greenberg DC; Brown CH; Donovan JL; Hamdy FC; Martin RM; ProtecT Study Group Members; Neal DE

Stage shift in PSA-detected prostate cancers – effect modification by Gleason score

Journal of Medical Screening
2009, 16: 98-101
Pashayan N; Pharoah P; Neal DE; Hamdy FC; Donovan JL; Martin RM; Greenberg DC; Duffy SW

Current strategies for monitoring men with localised prostate cancer lack a strong evidence base: observational longitudinal study

British Journal of Cancer
2009, 101: 390-394
Metcalfe C; Tilling K; Davis MJ; Lane JA; Martin RM; Kynaston H; Powell PH; Neal DE; Hamdy FC; Donovan JL

Multiple loci on 8q24 associated with prostate cancer susceptibility

Nature Genetics
2009, 41: 1058-1060
Al Olama AA; Kote Jarai Z; Giles GG; Guy M; Morrison J; Severi G; Leogamornlert DA; Tymrakiewicz M; Jhavar SG; Saunders E; Et al
120 **Psychological distress and prostate specific antigen levels in men with and without prostate cancer**

Brain, Behavior and Immunity
2009, 23: 1073-1078
Turner EL; Lane JA; Metcalfe C; Down L; Donovan JL; Hamdy FC; Neal DE; Vedhara K

126 **Mutation analysis of the MSMB gene in familial prostate cancer**

British Journal of Cancer
2009, 102: 414-418
Kote Jarai Z; Leogamornlert DA; Tymrakiewicz M; Field HI; Guy M; Al Olama AA; Morrison J; O'Brien LT; Wilkinson RA; Hall AM; Sawyer E; Muir KM; Hamdy FC; Donovan JL; Neal DE; Easton DF

128 **Screening for prostate cancer remains controversial**

The Lancet
2009, 374: 1482-1483
Neal DE; Donovan JL; Martin RM; Hamdy FC

139 **Identification of seven new prostate cancer susceptibility loci through a genome-wide association study**

Nature Genetics
2009, 41: 1116-1121
Eeles RA; Kote Jarai Z; Al Olama AA; Giles GG; Guy M; Severi G; Muir KM; Hopper JL; Henderson BE; Haiman CA; Schleutker J; Hamdy FC; Neal DE; Donovan JL; Et al

140 **A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer**

British Journal of Cancer
2009, 100: 426-430
Kote Jarai Z; Jugurnauth SK; Mulholland S; Leogamornlert DA; Guy M; Edwards SM; Tymrakiewicz M; O'Brien LT; Hall AM; Wilkinson RA; Al Olama AA; Morrison J; Muir KM; Neal DE; Donovan JL; Hamdy FC

41 **Low risk research using routinely collected identifiable health information without informed consent.**

Medical Ethics
2008, 34: 37-40
Metcalfe C; Martin RM; Noble S; Lane JA; Donovan JL

46 **Decision-Making about PSA Testing and Prostate Biopsies: A Qualitative Study Embedded in a Primary Care Randomised Trial**

European Urology
2008, 53: 1186-1193
Avery KNL; Blazeby JM; Lane JA; Neal DE; Hamdy FC; Donovan JL
54 Multiple newly identified loci associated with prostate cancer susceptibility
Nature Genetics
2008, 40: 316-321
Eeles RA; Kote Jarai Z; Giles GG; Al Olama AA; Guy M; Jugurnauth SK; Mulholland S; Daniel A; Leogamornlert DA; Edwards SM; Morrison J; Field HI; Southey MC; Severi G; Donovan JL; Hamdy FC

British Journal of Urology International
2008, 101: 547-555
Hussain S; Gunnell DJ; Donovan JL; McPhail S; Hamdy FC; Neal DE; Albertsen P; Verne J; Stephens P; Trotter C; Martin RM

56 Endogenous Sex Hormones and Prostate Cancer: A Collaborative Analysis of 18 Prospective Studies
Journal of the National Cancer Institute
2008, 100: 170-183
Roddam AW; Allen NE; Appleby P; Key TJ

56 Prostate cancer mortality in the USA and UK 1975 - 2004: an ecological study
Lancet Oncology
2008, 9: 445-452
Collin SM; Martin RM; Metcalfe C; Gunnell DJ; Albertsen P; Neal DE; Hamdy FC; Stephens P; Lane JA; Moore R; Donovan JL

61 Height and prostate cancer risk: a large nested case-control study (ProtecT) and meta-analysis
Cancer Epidemiology, Biomarkers & Prevention
2008, 17: 2325-2336
Zuccolo L; Harris R; Gunnell DJ; Oliver SE; Lane JA; Davis MJ; Donovan JL; Neal DE; Hamdy FC; Beynon R; Savovic J; Martin RM

63 Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer
British Journal of Urology International
2008, 102: 1400-1406
Collin SM; Metcalfe C; Donovan JL; Lane JA; Davis MJ; Neal DE; Hamdy FC; Martin RM

66 Insulin-like Growth Factors, their Binding Proteins and Prostate Cancer Risk: A Collaborative Analysis of Individual Data from Twelve Prospective Studies
Annals Internal Medicine
2008, 149: 461-471
Roddam AW; Allen NE; Appleby P; Key TJ
67 Multiple Loci with Different Cancer Specificities Within the 8q24 Gene Desert
Journal of the National Cancer Institute
2008, 100: 962-966
Ghoussaini M; Song H; Koessler T; Al Olama AA; Kote Jarai Z; Driver KE; Pooley KA; Ramus SJ; Kruger Kjaer S; Hogdall E; DiCioccio RA; Whittemore AS; Gayther SA; Giles GG; Guy M; Edwards SM

72 The decision-related psychosocial concerns of men with localised prostate cancer: targets for intervention and research
World Journal of Urology
2008, 26: 469-474
Steginga SK; Turner EL; Donovan JL

73 Prostate-specific antigen testing and prostate biopsy: are self-reported lower urinary tract symptoms and health-related quality of life associated with the decision to undergo these investigations?
British Journal of Urology International
2008, 102: 1629-1633
Avery KNL; Metcalfe C; Blazeby JM; Lane JA; Neal DE; Hamdy FC; Donovan JL

141 Multiple Novel Prostate Cancer Predisposition Loci Confirmed by an International Study: The PRACTICAL Consortium
Cancer Epidemiology Biomarkers and Prevention
2008, 17: 2052-2061
Kote Jarai Z; Easton DF; Stanford JL; Ostrander EA; Schleutker J; Ingles SA; Et al

45 Contribution of a single repeat PSA test to prostate cancer risk assessment - experience from the ProtecT Study.
European Urology
2007, 53: 777-784
Rosario DJ; Lane JA; Metcalfe C; Catto JW; Dedman DJ; Donovan JL; Neal DE; Hamdy FC

48 Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial.
British Medical Journal
2007, 335: 1139-1143
Lane JA; Howson J; Donovan JL; Goepel JR; Dedman DJ; Down L; Turner EL; Neal DE; Hamdy FC

50 Establishing normal reference ranges for prostate volume change with age in the population-based Krimpen-study: prediction of future prostate volume in individual men
The Prostate
2007, 67: 1816-1824
Bosch JLHR; Tilling K; Bohnen AM; Bangma C; Donovan JL
How ProtecT aims to improve treatment for men with prostate cancer
Oncology Times
2007, 4: 6
Salter L

Prostate cancer is omnipresent, but should we screen for it?
International Journal of Epidemiology
2007, 36: 278-281
Martin RM

Screening for prostate cancer.
(Book chapter)
2006, 3: 102-110
Hamdy FC; Donovan JL; Neal DE

Establishing Normal Reference Ranges for PSA Change With Age in a Population-Based Study: The Krimpen-Study
The Prostate
2006, 66: 335-343
Bosch JLHR; Tilling K; Bohnen AM; Donovan JL

Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the Prostate Specific Antigen Era.
Journal of Urology
2006, 176: 439-449
Martin RM; Gunnell DJ; Hamdy FC; Neal DE; Lane JA; Donovan JL

Screening for prostate cancer.
Trends in Urology Gynaecology and Sexual Health
2006, 11: 20-25
Martin RM; Donovan JL; Verne J

A comparison of socio-demographic and psychological factors between patients consenting to randomisation and those selecting treatment (the ProtecT) study.
Contemporary Clinical Trials
2006, 27: 413-419
Mills N; Metcalfe C; Ronsmans C; Davis MJ; Lane JA; Sterne JAC; Peters TJ; Hamdy FC; Neal DE; Donovan JL

A model of the natural history of screen-detected prostate cancer.
British Journal of Cancer
2006, 95: 1122-1123
Metcalfe C; Lane JA; Hamdy FC; Neal DE; Donovan JL
36 Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.
British Journal of Urology International
2006, 98: 777-782
Brindle LA; Oliver SE; Dedman DJ; Donovan JL; Neal DE; Hamdy FC; Lane JA; Peters TJ

44 Statins and risk of cancer: A systematic review and meta-analysis
International Journal of Cancer
2006, 120: 833-843
Browning DRL; Martin RM

22 Screening for prostate cancer - the case against.
Annals of the Royal College of Surgeons
2005, 87: 90-91
Donovan JL; Hamdy FC; Neal DE

23 Screening for prostate cancer - from the Year in Urology.
The Year in Urology
2005, 2: 152-166
Donovan JL

24 Reviewing negative prostatic core biopsies for the multidisciplinary team meeting.
Histopathology
2005, 47: 643-644
Oxley J

25 Does current evidence justify prostate cancer screening in Europe?
Nature Clinical Practice Oncology Review
2005, 2: 538-539
Martin RM; Davey Smith G; Donovan JL

26 Prostate cancer: Screening approaches.
British Journal of Hospital Medicine
2005, 66: 623-626
Donovan JL; Martin RM; Neal DE; Hamdy FC

19 Serum insulin-like growth factor-I is positively associated with serum prostate-specific antigen in middle-aged men without evidence of prostate cancer.
Cancer Epidemiology Biomarkers and Prevention
2004, 13: 163-165
Oliver SE; Barass B; Gunnell DJ; Donovan JL; Peters TJ; Persad RA; Gillatt D; Neal DE; Hamdy FC; Holly JMP
20 Screen-detected prostate cancer and the insulin-like growth factor axis: results of a population-based case-control study.
International Journal of Cancer
2004, 108: 887-892
Oliver SE; Gunnell DJ; Donovan JL; Peters TJ; Persad RA; Gillatt D; Pearce A; Neal DE; Hamdy FC; Holly JMP

21 Do height-related variations in insulin-like growth factors underlie the associations of stature with adult chronic disease?
Journal of Clinical Endocrinology and Metabolism
2004, 89: 213-218
Gunnell DJ; Oliver SE; Hamdy FC; Neal DE; Holly JMP

33 Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
Urology
2004, 64: 317-322
Oliver SE; Holly JMP; Peters TJ; Donovan JL; Persad RA; Gillatt D; Pearce A; Hamdy FC; Neal DE; Gunnell DJ

1 Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study
Controlled Clinical Trials
2003, 24: 272-282
Mills N; Donovan JL; Smith M; Jacoby A; Neal DE; Hamdy FC

2 Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study)
Journal of Clinical Epidemiology
2003, 56: 605-609
Donovan JL; Peters TJ; Noble S; Powell PH; Gillatt D; Oliver SE; Lane JA; Neal DE; Hamdy FC

British Journal of Urology International
2003, 91: 331-336
Oliver SE; Donovan JL; Peters TJ; Frankel SJ; Hamdy FC; Neal DE

British Journal of Cancer
2003, 88: 1682-1686
Gunnell DJ; Oliver SE; Peters TJ; Donovan JL; Persad RA; Maynard M; Gillatt D; Pearce A; Hamdy FC; Neal DE; Holly JMP
16 Ethics of clinical trials from bayesian perspective: Randomisation to clinical trials may solve dilemma of treatment choice in prostate cancer.
British Medical Journal
2003, 326: 1456-1456
Hamdy FC; Donovan JL; Lane JA; Neal DE

17 Prostate Testing for Cancer and Treatment (ProtecT) feasibility study.
Health Technology Assessment
2003, 7
Donovan JL; Hamdy FC; Neal DE; Peters TJ; Oliver SE; Brindle LA; Jewell D; Powell PH; Gillatt D; Dedman DJ; Mills N; Smith M; Noble S; Lane JA

18 Screening for prostate cancer.
The Lancet
2003, 361: 1122-1128
Frankel SJ; Davey Smith G; Donovan JL; Neal DE

12 Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT study.
British Medical Journal
2002, 325: 766-770
Donovan JL; Mills N; Smith M; Brindle LA; Jacoby A; Peters TJ; Frankel SJ; Neal DE; Hamdy FC; Little P

13 Clinical oncologists favour radical radiotherapy for localised prostate cancer: a questionnaire survey.
British Journal of Urology International
2002, 90: 558-560
Hanna CL; Mason MD; Donovan JL; Barber JP

European Journal of Public Health
2000, 10: 289-295
Faulkner A; Brookes ST; Donovan JL; Selley S; Gillatt D; Hamdy FC

7 Comparison of trends in prostate-cancer mortality in England, Wales and the USA.
The Lancet
2000, 355: 1788-1789
Oliver SE; Gunnell DJ; Donovan JL

8 Unanswered questions in screening for prostate cancer.
European Journal of Cancer
2000, 36: 1316-1321
Neal DE; Leung HY; Powell PH; Hamdy FC; Donovan JL
9 Prostate cancer: to screen or not to screen?
The Lancet Oncology
2000, 1: 17-24
Neal DE; Donovan JL

10 Screening for prostate cancer in the UK: Seems to be creeping in by the back door.
British Medical Journal
2000, 323: 763-764
Donovan JL; Frankel SJ; Neal DE; Hamdy FC

11 Capturing users’ experiences of participating in cancer trials.
European Journal of Cancer Care
2000, 11: 210-214
Donovan JL; Brindle LA; Mills N

5 Dilemmas in treating early prostate cancer: the evidence and a questionnaire survey of consultant urologists in the United Kingdom.
British Medical Journal
1999, 318: 299-300
Donovan JL; Frankel SJ; Faulkner A; Selley S; Gillatt D; Hamdy FC

4 Screening for prostate cancer.
Annals of Oncology
1998, 9: 1289-1292
Neal DE; Donovan JL

3 Diagnosis, management and screening of early localised prostate cancer: a review
Health Technology Assessment
1997, 1: 156-156
Selley S; Donovan JL; Faulkner A; Coast J; Gillatt D

89 Do variations in IGFs underlie the associations of adiposity with prostate cancer? A cross-sectional analysis of body shape, IGF-I, IGF-II, IGFBP-2 and IGFBP-3 in healthy middle-aged men.
Cancer Causes and Control
Rowlands MA; Martin RM; Gunnell DJ; Holly JMP; Collin SM; Marsden G; Neal DE; Hamdy FC; Donovan JL; Lane JA